|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
|
EP0590058B1
(en)
|
1991-06-14 |
2003-11-26 |
Genentech, Inc. |
HUMANIZED Heregulin ANTIBODy
|
|
GB9510716D0
(en)
*
|
1995-05-26 |
1995-07-19 |
Pharmacia Spa |
Substituted camptothecin derivatives and process for their preparation
|
|
US5714586A
(en)
|
1995-06-07 |
1998-02-03 |
American Cyanamid Company |
Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
|
|
US7087411B2
(en)
|
1999-06-08 |
2006-08-08 |
Regeneron Pharmaceuticals, Inc. |
Fusion protein capable of binding VEGF
|
|
US6596541B2
(en)
|
2000-10-31 |
2003-07-22 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
|
US20070258987A1
(en)
|
2000-11-28 |
2007-11-08 |
Seattle Genetics, Inc. |
Recombinant Anti-Cd30 Antibodies and Uses Thereof
|
|
CN100406460C
(zh)
|
2003-11-10 |
2008-07-30 |
中国科学院上海药物研究所 |
喜树碱的新衍生物、制备方法和用途
|
|
TW200539855A
(en)
|
2004-03-15 |
2005-12-16 |
Wyeth Corp |
Calicheamicin conjugates
|
|
NZ551180A
(en)
|
2004-06-01 |
2009-10-30 |
Genentech Inc |
Antibody drug conjugates and methods
|
|
CN1587265A
(zh)
|
2004-07-08 |
2005-03-02 |
浙江大学 |
10-烷氧基喜树碱衍生物及其制备方法与应用
|
|
US20080305044A1
(en)
|
2004-11-29 |
2008-12-11 |
Seattle Genetics, Inc. |
Engineered Antibodies and Immunoconjugates
|
|
US7750116B1
(en)
|
2006-02-18 |
2010-07-06 |
Seattle Genetics, Inc. |
Antibody drug conjugate metabolites
|
|
RU2448979C2
(ru)
|
2006-12-14 |
2012-04-27 |
Ридженерон Фармасьютикалз, Инк. |
Антитела человека к дельта-подобному лиганду-4 человека
|
|
WO2008122039A2
(en)
|
2007-04-02 |
2008-10-09 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Selenocysteine mediated hybrid antibody molecules
|
|
US7985557B2
(en)
|
2007-05-23 |
2011-07-26 |
Ventana Medical Systems, Inc. |
Polymeric carriers for immunohistochemistry and in situ hybridization
|
|
UA108598C2
(xx)
|
2008-04-30 |
2015-05-25 |
|
Високоефективні кон'югати та гідрофільні зшиваючі агенти (лінкери)
|
|
ES2560807T3
(es)
|
2008-07-21 |
2016-02-22 |
Polytherics Limited |
Nuevos reactivos y procedimiento de conjugación de moléculas biológicas
|
|
KR101000067B1
(ko)
|
2008-12-30 |
2010-12-10 |
엘지전자 주식회사 |
고효율 태양전지용 레이저 소성장치 및 고효율 태양전지 제조방법
|
|
JO3182B1
(ar)
|
2009-07-29 |
2018-03-08 |
Regeneron Pharma |
مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
|
|
DK2889624T3
(en)
|
2009-08-10 |
2018-12-10 |
Ucl Business Plc |
Reversible covalent bonding of functional molecules
|
|
PT2528625E
(pt)
|
2010-04-15 |
2013-10-17 |
Spirogen Sarl |
Pirrolobenzodiazepinas e conjugados das mesmas
|
|
US20130244905A1
(en)
|
2010-07-06 |
2013-09-19 |
Ed Grabczyk |
Reporter for RNA Polymerase II Termination
|
|
EP2601298B1
(en)
|
2010-08-02 |
2016-11-30 |
Regeneron Pharmaceuticals, Inc. |
Mice that make binding proteins comprising vl domains
|
|
DK2714685T3
(en)
|
2011-05-27 |
2017-01-09 |
Ambrx Inc |
FORMATIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACID BOUND dolastatin
|
|
US8815226B2
(en)
|
2011-06-10 |
2014-08-26 |
Mersana Therapeutics, Inc. |
Protein-polymer-drug conjugates
|
|
JP6166728B2
(ja)
|
2011-10-14 |
2017-07-19 |
メドイミューン・リミテッドMedImmune Limited |
ピロロベンゾジアゼピンの製造に有用な合成方法及び中間体
|
|
AU2012322934B2
(en)
|
2011-10-14 |
2016-09-08 |
Medimmune Limited |
Pyrrolobenzodiazepines
|
|
CA2850373C
(en)
|
2011-10-14 |
2019-07-16 |
Seattle Genetics, Inc. |
Pyrrolobenzodiazepines and targeted conjugates
|
|
CA2850375C
(en)
|
2011-10-14 |
2019-07-02 |
Seattle Genetics, Inc. |
Pyrrolobenzodiazepines and targeted conjugates
|
|
WO2013068874A1
(en)
|
2011-11-11 |
2013-05-16 |
Pfizer Inc. |
Antibody-drug conjugates
|
|
BR112014013526A8
(pt)
|
2011-12-05 |
2017-06-13 |
Igenica Biotherapeutics Inc |
conjugados de anticorpo-fármaco e compostos, composições e métodos relacionados
|
|
HRP20180268T4
(hr)
|
2012-10-23 |
2026-03-27 |
Synaffix B.V. |
Modificirano antitijelo, konjugat antitijela i postupak za njihovu pripremu
|
|
TWI871999B
(zh)
*
|
2014-04-10 |
2025-02-01 |
日商第一三共股份有限公司 |
抗her3抗體-藥物結合物
|
|
WO2015187596A2
(en)
|
2014-06-02 |
2015-12-10 |
Regeneron Pharmaceuticals, Inc. |
Biologically active molecule conjugates, reagents and methods of manufacture, and therapeutic uses
|
|
MX390630B
(es)
|
2016-01-25 |
2025-03-21 |
Regeneron Pharma |
Derivados de maitansinoide, conjugados de los mismos y metodos de uso.
|
|
EP3419670A2
(en)
|
2016-02-26 |
2019-01-02 |
Regeneron Pharmaceuticals, Inc. |
Optimized transglutaminase site-specific antibody conjugation
|
|
WO2018026742A1
(en)
*
|
2016-08-01 |
2018-02-08 |
Askgene Pharma Inc. |
Novel antibody-albumin-drug conjugates (aadc) and methods for using them
|
|
CA3042428A1
(en)
|
2016-11-08 |
2018-05-17 |
Regeneron Pharmaceuticals, Inc. |
Steroids and protein-conjugates thereof
|
|
EP3700577A1
(en)
*
|
2017-10-23 |
2020-09-02 |
Mablink Bioscience |
Ligand-drug-conjugate comprising a single molecular weight polysarcosine
|
|
JP7328990B2
(ja)
|
2018-04-30 |
2023-08-17 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
Her2及び/またはaplp2に結合する抗体及び二重特異性抗原結合分子、ならびにそれらのコンジュゲート及び使用
|
|
WO2019217591A1
(en)
*
|
2018-05-09 |
2019-11-14 |
Regeneron Pharmaceuticals, Inc. |
Anti-msr1 antibodies and methods of use thereof
|
|
EP3794042B1
(en)
*
|
2018-05-18 |
2024-03-27 |
Daiichi Sankyo Co., Ltd. |
Anti-muc1- exatecan antibody-drug conjugate
|
|
JP2022517767A
(ja)
|
2019-01-08 |
2022-03-10 |
レゲネロン ファーマシューティカルス,インコーポレーテッド |
無痕跡型リンカー及びそのタンパク質-コンジュゲート
|
|
EP3976112A1
(en)
*
|
2019-06-03 |
2022-04-06 |
Synaffix B.V. |
Acetal-based cleavable linkers
|
|
CA3166619A1
(en)
*
|
2020-02-28 |
2021-09-02 |
Julian Andreev |
Bispecific antigen binding molecules that bind her2, and methods of use thereof
|
|
US12605459B2
(en)
*
|
2020-07-13 |
2026-04-21 |
Regeneron Pharmaceuticals, Inc. |
Protein-drug conjugates comprising camptothecin analogs and methods of use thereof
|
|
US20250122282A2
(en)
*
|
2020-09-04 |
2025-04-17 |
Merck Patent Gmbh |
Anti-ceacam5 antibodies and conjugates and uses thereof
|
|
MX2023011630A
(es)
*
|
2021-03-30 |
2024-01-24 |
Mablink Bioscience |
Enlace autorreactivo activado por enzima que tiene propiedades fisicoquimicas y farmacologicas mejoradas.
|
|
AU2022269073A1
(en)
*
|
2021-05-07 |
2023-11-23 |
ALX Oncology Inc. |
Exatecan derivatives and antibody-drug conjugates thereof
|
|
MX2023012920A
(es)
*
|
2021-06-02 |
2023-11-13 |
Sichuan Kelun Biotech Biopharmaceutical Co Ltd |
Conjugado anticuerpo-farmaco y metodo de preparacion y uso del mismo.
|
|
EP4545096A1
(en)
*
|
2022-06-27 |
2025-04-30 |
Trioar, Inc. |
Compound comprising self-immolative group and ligand-drug conjugate comprising same
|